Table 4.
Adverse Events and Lab Abnormalities
| Total | Supportive Care | Remdesivir | P Value | |
|---|---|---|---|---|
| n = 224 | n = 125 | n = 99 | ||
| Acute kidney injury | .12 | |||
| Stage 1 | 31 (52) | 17 (50) | 14 (54) | |
| Stage 2 | 5 (8) | 5 (15) | 0 (0) | |
| Stage 3 | 24 (40) | 12 (35) | 12 (46) | |
| Aspartate aminotransferase increase | .20 | |||
| Grade 1 | 66 (96) | 31 (91) | 35 (100) | |
| Grade 2 | 1 (1) | 1 (3) | 0 (0) | |
| Grade 3 | 2 (3) | 2 (6) | 0 (0) | |
| Alanine aminotransferase increase | .25 | |||
| Grade 1 | 63 (95) | 32 (91) | 31 (100) | |
| Grade 2 | 0 (0) | 0 (0) | 0 (0) | |
| Grade 3 | 2 (3) | 2 (6) | 0 (0) | |
| Grade 4 | 1 (2) | 1 (3) | 0 (0) | |
| Serum total bilirubin increase | .94 | |||
| Grade 1 | 16 (47) | 8 (44) | 8 (50) | |
| Grade 2 | 11 (32) | 6 (33) | 5 (31) | |
| Grade 3 | 7 (21) | 4 (22) | 3 (19) |
Data are presented as No. (%). ALT, AST, and bilirubin were graded using CTCAE, version 5.0. AKI was graded according to the KDIGO criteria.
Abbreviations: AKI, acute kidney injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events.